Immune targets for therapeutic development in depression: towards precision medicine
Over the past two decades, compelling evidence has emerged indicating that immune
mechanisms can contribute to the pathogenesis of major depressive disorder (MDD) and …
mechanisms can contribute to the pathogenesis of major depressive disorder (MDD) and …
The role of 5-HT receptors in depression
Depression is a polygenic and highly complex psychiatric disorder that remains a major
burden on society. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) …
burden on society. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) …
[HTML][HTML] Single-dose psilocybin for a treatment-resistant episode of major depression
Background Psilocybin is being studied for use in treatment-resistant depression. Methods
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
Cross-trial prediction of treatment outcome in depression: a machine learning approach
Background Antidepressant treatment efficacy is low, but might be improved by matching
patients to interventions. At present, clinicians have no empirically validated mechanisms to …
patients to interventions. At present, clinicians have no empirically validated mechanisms to …
Assessing anhedonia in depression: Potentials and pitfalls
The resurgence of interest in anhedonia within major depression has been fuelled by
clinical trials demonstrating its utility in predicting antidepressant response as well as recent …
clinical trials demonstrating its utility in predicting antidepressant response as well as recent …
Inflammation and clinical response to treatment in depression: a meta-analysis
The depressive state has been characterised as one of elevated inflammation, which holds
promise for better understanding treatment-resistance in affective disorders as well as for …
promise for better understanding treatment-resistance in affective disorders as well as for …
Toward a deeper understanding of gut microbiome in depression: the promise of clinical applicability
L Liu, H Wang, H Zhang, X Chen, Y Zhang… - Advanced …, 2022 - Wiley Online Library
The emergence of the coronavirus disease 2019 pandemic has dramatically increased the
global prevalence of depression. Unfortunately, antidepressant drugs benefit only a small …
global prevalence of depression. Unfortunately, antidepressant drugs benefit only a small …
The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature
Background Major depressive disorder (MDD) is a global public health concern. In
particular, treatment-resistant depression (TRD) represents a key unmet need in the …
particular, treatment-resistant depression (TRD) represents a key unmet need in the …
Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression
M Hibicke, AN Landry, HM Kramer… - ACS chemical …, 2020 - ACS Publications
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more
months after only one or two treatments. Another hallucinogenic drug, esketamine, has …
months after only one or two treatments. Another hallucinogenic drug, esketamine, has …
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety …
BackgroundKetamine and non-ketamine N-methyl-d-aspartate receptor antagonists
(NMDAR antagonists) recently demonstrated antidepressant efficacy for the treatment of …
(NMDAR antagonists) recently demonstrated antidepressant efficacy for the treatment of …